-+ 0.00%
-+ 0.00%
-+ 0.00%

CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55

Benzinga·07/13/2026 13:32:24
Listen to the news

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $42 to $55.